Wolfson Brain Imaging Centre (WBIC), part of Cambridge University in the United Kingdom (UK), is a facility dedicated to imaging functions in the injured human brain using Positron Emission Tomography and Magnetic Resonance systems. 

A new MAGNETOM^®  Verio 3T magnetic resonance imaging (MRI) scanner was recently installed at WBIC. This installation was funded by the Clinical Research Infrastructure (CRI) initiative from the UK Clinical Research Collaboration (UKCRC) led by the Wellcome Trust. The CRI initiative provides funding to facilities that undertake experimental medicine and translational clinical research in the UK.

MAGNETOM Verio 3T offers a combination of the strongest clinically used magnetic field strength, the 70-centimeter Open Bore design, and Tim^® (Total imaging matrix) technology to create one powerful MRI system. The 70-centimeter Open Bore design provides ease and care for a wider range of patients and allows for sharper images due to less anxiety-related movement. It accommodates obese, pediatric, ICU, claustrophobic, and elderly patients. Created to improve performance, Tim technology makes workflow more efficient, shortens scan time and thereby increases throughput by offering flexibility, accuracy, and speed with its ultra-lightweight Matrix coils. In summary, MAGNETOM Verio provides outstanding diagnostic capabilities, patient comfort, and efficient workflow.

MAGNETOM Verio will be utilized by researchers from the University of Cambridge, Addenbrookes Hospital Trust, and the Institute of Metabolic Science (newly established) to undertake magnetic resonance spectroscopy (MRS) in a range of disorders, such as insulin resistance, diabetes, obesity, or endocrine and metabolic storage diseases. Biochemical processes and pathways in tissue no longer need to be measured using invasive biopsy since MRS technology can now replace this procedure. The knowledge attained through this research will provide a better understanding of how metabolic pathways are deranged in various disorders.   “The MAGNETOM Verio will allow us to develop MRS as a biomarker in clinical metabolic research,” states Adrian Carpenter, Director of MR and Reader in Imaging Sciences at the WBIC. “The system is performing well and has lived up to all our expectations. We are looking forward to beginning studies on the Verio shortly and are positive it will assist with our research efforts.”